The prognosis of metastatic renal cell cancer (RCC) is poor due to the lack of an effective treatment. Continuous circadian infusion of FUDR (5-fluoro-deoxyuridine) by the implantable Synchromed-Medtronic infusion system achieves an effective response in 24% of cases. The association with interferon seems to increase response rate. The Authors report their preliminary experience in 5 patients with metastatic RCC treated with chronoinfusion of FUDR and interferon. All patients tolerated the treatment well and no major toxicity was observed.
ProutG.R.Jr.GarnickM.B.: The Kidney and Urether. Chap. XXVI-2. In Holland J., Frei E. III, Cancer Medicine; Lea and Febiger, Philadelphia, III ed. 1990.
2.
RosenbergS.A.LotzeM.T.MuléJ.J.: New approaches to the immunotherapy of cancer using interleukin-2. Ann. Int. Med., 108, 853–864, 1988.
3.
RosembergS.A.LotzeM.T.YangJ.C., and Coll.: Combination therapy with interleukin-2 and alpha interferon for treatment of patients with advanced cancer. J. Clin. Oncol. 7, 12: 1863–1874, 1989.
4.
HrusheskyW.J.M.RoemelingV.R.FraleyE.E.: Circadian based chrono-chemioterapy controls progressive metastatic renal cell carcinoma. Seminars in Surgical Oncology, 4: 110–115, 1988.
5.
QuesadaJ.R.SwansonD.A.: Renal carcinoma: antitumor effects of leukocyte interferon. Cancer Res., 43: 940, 1983.
6.
NeidhartJ.A.GagenM.: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Cancer Res., 44: 41, 40, 1984.
7.
BelldegrunA.RosenbergS.A.: Adoptive immunotherapy of urologic tumors. Cancer treat. Res., 46: 213–33, 1989.
8.
BuddG.T.SergiJ.FinkleJ., and Coll.: Combination Interleukin-2 and alpha-interferon therapy of metastatic renal cell carcinoma and malignant melanoma. Proc. Annu. 8 Meet. Am. Assoc. Cancer. Res., 31: A1603, 1990.
9.
HirshM.LiptonA.HarveyH., and Coll.: Phase I study of interleukin-2 and interferon alpha-2a as outpatient therapy for patients with advanced malignancy. J. Clin. Oncol., 8: 1657–1659, 1990.
10.
DimopoulosM.A.DexeusF.H.JonesE., and Coll.: Evidence of additive antitumor activity and toxicity for the combination of FUDR and interferon alpha 2B (IFN-ALPHA INTRON) in patients with metastatic renal cell carcinoma (RCC).
11.
EsgroJ.J.KillionJ.J.FidlerI.J.: Modulation of the antiproliferative effects of Fluoxiurudine by interferon beta against human colon carcinoma cells. Proc. Annu. Meet. Am. Assoc. cancer Res., 31: A2525, 1990.
12.
ContiG.CappoliS.GianneoE., and Coll.: Continuous chemotherapy with fluoxiuridine (FUDR) by an implantable programmable pump in renal cell carcinoma (RCC): 3-year experience. European Urol., 18 (Suppl. 1): 147, 1990.
13.
DamascelliB.MarchianoASpreaficoC., and Coll.: Circadian continuous chemotherapy of renal cell carcinoma with an implantable programmable infusion pump. Cancer, 66(2): 237–41, 1990.
